600,002,000 Common Shares of Medilines Distributors Incorporated are subject to a Lock-Up Agreement Ending on 7-DEC-2022.
December 06, 2022
Share
600,002,000 Common Shares of Medilines Distributors Incorporated are subject to a Lock-Up Agreement Ending on 7-DEC-2022. These Common Shares will be under lockup for 365 days starting from 7-DEC-2021 to 7-DEC-2022.
Details:
Existing shareholders who own an equivalent of at least 10% of the issued and outstanding Shares as of the Listing Date cannot sell, assign or. in any manner dispose of their Shares for a minimum period of 180 days after the Listing Date. Thus, the following shall be subject to such lock-up period, 1,005,002,800 common shares held by Virgilio B. Villar and 319,996,000 common shares held by Theresa V. Villar.
In addition, if there is any issuance or transfer of Shares (i.e., private placements, asset for shares swap or a similar transaction) or instruments which lead to issuance of Shares (i.e., convertible bonds, warrants or a similar instrument) completed and fully paid for within 180 days prior to the start of the Offer, and the transaction price is lower than that of the Offer Price in the initial public offering, all such Shares issued or transferred shall be subject to a lock-up period of at least 365 days from full payment of such Shares. Thus, the following shall be subject to such lock-up period 600,000,000 common shares held by Two On, Inc., 400 common shares each held by Maria Patricia Dolor V. Yambing, Norman K. Macapagal, Fernando Sixto V. Segovia, Brian N. Edang and Gerardo J. Guerrero.
Medilines Distributors, Inc. is a Philippines-based distributor of critical medical equipment to public and private healthcare facilities across the Philippines. Its products such as linear accelerators for cancer treatment, dialysis machines for treatment of kidney diseases, and imaging machines such as computerized tomography (CT), x-rays, and magnetic resonance imaging (MRI). It is focused on three core categories: diagnostics imaging, dialysis, and cancer therapy. It manufactures equipment in advanced therapy, which includes C-Arm, Cathlab, Robotics. Its Molecular Imaging, which includes PET CT and SPECT CT. Its renal care includes dialysis machines, consumables, and accessories. Its radiation therapy includes Varian Halcyon, and Varian True Beam. Its diagnostic imaging products include Multix Impact, Elara Max, Polymobil Plus, and Magnetom Skyra. Its brands include Siemens Healthineers for diagnostic imaging, B. Braun for dialysis, and Varian for cancer therapy.